Delphine Vivier1, Sai Kiran Sharma2, Pierre Adumeau1, Cindy Rodriguez1, Kimberly Fung1,3, Brian M Zeglis4,2,3. 1. Department of Chemistry, Hunter College of the City University of New York, New York, New York. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and. 3. Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York. 4. Department of Chemistry, Hunter College of the City University of New York, New York, New York bz102@hunter.cuny.edu.
Abstract
Antibodies are promising vectors for PET imaging. However, the high uptake of radioimmunoconjugates in nontarget tissues such as the liver and spleen hampers their performance as radiotracers. This off-target uptake can lead to suboptimal tumor-to-background activity concentration ratios, decreasing the contrast of images and reducing their diagnostic utility. A possible cause of this uptake is the sequestration of radioimmunoconjugates by immune cells bearing Fc-γ-receptors (FcγR) that bind to the Fc regions of antibodies. Methods: Since the heavy chain glycans influence the affinity of FcγR for the Fc domain, we set out to investigate whether radioimmunoconjugates with truncated glycans would exhibit altered binding to FcγRI and, in turn, improved in vivo performance. Using the HER2-targeting antibody trastuzumab, we synthesized a series of desferrioxamine-bearing immunoconjugates with differing glycosylation states and interrogated their FcγRI binding via surface plasmon resonance, enzyme-linked immunosorbent assay, and flow cytometry. Furthermore, we labeled these immunoconjugates with 89Zr and explored their biodistribution in athymic nude, NSG, and humanized NSG mice bearing human epidermal growth factor receptor 2-expressing human breast cancer xenografts. Results: We observed a strong correlation between the impaired in vitro FcγRI binding of deglycosylated immunoconjugates and significant decreases in the in vivo off-target uptake of the corresponding 89Zr-labeled radioimmunoconjugates (i.e., liver activity concentrations are reduced by ∼3.5-fold in humanized NSG mice). These reductions in off-target uptake were accompanied by concomitant increases in the tumoral activity concentrations of the glycoengineered radioimmunoconjugates, ultimately yielding improved tumor-to-healthy organ contrast and higher quality PET images. Conclusion: Our findings suggest that the deglycosylation of antibodies represents a facile strategy for improving the quality of immuno-PET in animal models as well as in certain patient populations.
Antibodies are promising vectors for PET imaging. However, the high uptake of radioimmunoconjugates in nontarget tissues such as the liver and spleen hampers their performance as radiotracers. This off-target uptake can lead to suboptimal tumor-to-background activity concentration ratios, decreasing the contrast of images and reducing their diagnostic utility. A possible cause of this uptake is the sequestration of radioimmunoconjugates by immune cells bearing Fc-γ-receptors (FcγR) that bind to the Fc regions of antibodies. Methods: Since the heavy chain glycans influence the affinity of FcγR for the Fc domain, we set out to investigate whether radioimmunoconjugates with truncated glycans would exhibit altered binding to FcγRI and, in turn, improved in vivo performance. Using the HER2-targeting antibody trastuzumab, we synthesized a series of desferrioxamine-bearing immunoconjugates with differing glycosylation states and interrogated their FcγRI binding via surface plasmon resonance, enzyme-linked immunosorbent assay, and flow cytometry. Furthermore, we labeled these immunoconjugates with 89Zr and explored their biodistribution in athymic nude, NSG, and humanized NSG mice bearing humanepidermal growth factor receptor 2-expressing humanbreast cancer xenografts. Results: We observed a strong correlation between the impaired in vitro FcγRI binding of deglycosylated immunoconjugates and significant decreases in the in vivo off-target uptake of the corresponding 89Zr-labeled radioimmunoconjugates (i.e., liver activity concentrations are reduced by ∼3.5-fold in humanized NSG mice). These reductions in off-target uptake were accompanied by concomitant increases in the tumoral activity concentrations of the glycoengineered radioimmunoconjugates, ultimately yielding improved tumor-to-healthy organ contrast and higher quality PET images. Conclusion: Our findings suggest that the deglycosylation of antibodies represents a facile strategy for improving the quality of immuno-PET in animal models as well as in certain patient populations.
Authors: Pierre Bruhns; Bruno Iannascoli; Patrick England; David A Mancardi; Nadine Fernandez; Sylvie Jorieux; Marc Daëron Journal: Blood Date: 2008-11-18 Impact factor: 22.113
Authors: Jordan M White; Outi M Keinänen; Brendon E Cook; Brian M Zeglis; Heather M Gibson; Nerissa T Viola Journal: Mol Pharm Date: 2020-05-12 Impact factor: 4.939
Authors: Harm Westdorp; Sarah R Verhoeff; Martin Gotthardt; Carla M L van Herpen; Michel M van; den Heuvel; Sandra Heskamp; Erik H J G Aarntzen Journal: J Nucl Med Date: 2022-01-20 Impact factor: 10.057
Authors: Syed Muhammad Usama; Ek Raj Thapaliya; Michael P Luciano; Martin J Schnermann Journal: Curr Opin Chem Biol Date: 2021-03-05 Impact factor: 8.972
Authors: Francesco Cicone; Silvano Gnesin; Thibaut Denoël; Thierry Stora; Nicholas P van der Meulen; Cristina Müller; Christiaan Vermeulen; Martina Benešová; Ulli Köster; Karl Johnston; Ernesto Amato; Lucrezia Auditore; George Coukos; Michael Stabin; Niklaus Schaefer; David Viertl; John O Prior Journal: EJNMMI Res Date: 2019-06-11 Impact factor: 3.138
Authors: Matthew Farleigh; Truc Thuy Pham; Zilin Yu; Jana Kim; Kavitha Sunassee; George Firth; Nafsika Forte; Vijay Chudasama; James R Baker; Nicholas J Long; Charlotte Rivas; Michelle T Ma Journal: Bioconjug Chem Date: 2021-03-16 Impact factor: 4.774